Literature DB >> 11245427

Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.

A Eggert1, M A Grotzer, T J Zuzak, B R Wiewrodt, R Ho, N Ikegaki, G M Brodeur.   

Abstract

Disruption of apoptotic pathways may be involved in tumor formation, regression, and treatment resistance of neuroblastoma (NB). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cell lines, whereas normal cells are not sensitive to TRAIL-mediated apoptosis. In this study we analyzed the expression and function of TRAIL and its agonistic and antagonistic receptors as well as expression of cellular FLICE-like inhibitory protein and caspase-2, -3, -8, -9, and -10 in 18 NB cell lines. Semiquantitative RT-PCR revealed that TRAIL-R2 and TRAIL-R3 are the main TRAIL-receptors used by NB cells. Sensitivity to TRAIL-induced apoptosis did not correlate with mRNA expression of TRAIL receptors or cellular FLICE-like inhibitory protein. Surprisingly, caspase-8 and caspase-10 mRNA expression was detected in only 5 of 18 NB cell lines. Interestingly, only these five NB cell lines were susceptible to TRAIL-induced apoptosis in a time- and dose-dependent manner. Treatment with 5-aza-2'-deoxycytidine restored mRNA and protein expression of caspase-8 and TRAIL sensitivity of resistant cell lines, suggesting that gene methylation is involved in caspase inactivation. The TRAIL system seems to be functional in NB cells expressing caspase-8 and/or caspase-10. Because many cytotoxic drugs induce caspase-dependent apoptosis, failure to express caspase-8 and/or caspase-10 might be an important mechanism of resistance to chemotherapy in NB.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

1.  Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins.

Authors:  Sahdeo Prasad; Jayaraj Ravindran; Bokyung Sung; Manoj K Pandey; Bharat B Aggarwal
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

2.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

3.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

4.  Targeting death receptors: is this trail still hot?

Authors:  Rajen Mody
Journal:  Transl Pediatr       Date:  2013-04

5.  Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).

Authors:  F Yang; P Shi; X Xi; S Yi; H Li; Q Sun; M Sun
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

7.  Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse.

Authors:  Chana L Glasser; Alice Lee; Don Eslin; Lianna Marks; Shakeel Modak; Julia L Glade Bender
Journal:  J Pediatr Hematol Oncol       Date:  2017-10       Impact factor: 1.289

8.  Prospective antitumor effects of the combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin against esophageal squamous cell carcinoma.

Authors:  Kan Kondo; Seiji Yamasaki; Naoya Inoue; Tomoharu Sugie; Naoki Teratani; Takatsugu Kan; Yutaka Shimada
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

9.  MYCN Silencing by RNAi Induces Neurogenesis and Suppresses Proliferation in Models of Neuroblastoma with Resistance to Retinoic Acid.

Authors:  Ruhina Maeshima; Dale Moulding; Andrew W Stoker; Stephen L Hart
Journal:  Nucleic Acid Ther       Date:  2020-04-02       Impact factor: 5.486

10.  Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells.

Authors:  Michael A Sheard; Shahab Asgharzadeh; Yin Liu; Tsen-Yin Lin; Hong-Wei Wu; Lingyun Ji; Susan Groshen; Dean A Lee; Robert C Seeger
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.